Marco Cacciuttolo PhD

Senior Vice President, Novavax

Marco has an extensive experience in leading biologics development from start-up stage to registration and commercial operations, introducing innovative approaches to process development and business value creation. He has fostered successful partnerships working with groups from different cultural backgrounds and locations around the world. Prior to joining Novavax in July 2020, Dr. Cacciuttolo served as head of manufacturing at Nosocomial Vaccine Corporation, chief operating officer at PathoVax LLC, and managing director of Batavia Biosciences. Earlier in his career, he held positions of increasing responsibility at MedImmune LLC, Medarex, Percivia LLC and Tetragenetics, Inc. Dr. Cacciuttolo received a bachelor’s degree in biochemical engineering from Pontifical Catholic University of Valparaíso and a doctorate in biochemical engineering from the University of Maryland, Baltimore. Novavax Company Profile: Novavax is a biotechnology company committed to improving health globally through the discovery, development, and delivery of innovative vaccines to help prevent serious infectious diseases. The company'sproprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received conditional authorization or approval from multiple regulatory authorities globally, including the European Commission and the World Health Organization, and is currently under review in additional countries worldwide for use in adults, adolescents, and as a booster. Novavax is also developing a COVID-seasonal influenza combination vaccine candidate and an Omicron strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.